ADVERTISEMENT
Adverse Events With Intravascular Lithotripsy After Peripheral and Off-Label Coronary Use: A Report From the FDA MAUDE Database
Yashasvi Chugh, MD1; Jaikirshan J. Khatri, MD2; Mehdi H. Shishehbor, DO, MPH, PhD3; Subhash Banerjee, MD4; Kevin Croce, MD5; Khaldoon Alaswad, MD6; Bilal Murad, MD1; Santiago Garcia, MD1; M. Nicholas Burke, MD1; Emmanouil S. Brilakis, MD, PhD1
1. Hill JM, Kereiakes DJ, Shlofmitz RA, et al. Intravascular lithotripsy for treatment of severely calcified coronary artery disease. J Am Coll Cardiol. 2020;76:2635-2646.
2. Brodmann M, Werner M, Brinton TJ, et al. Safety and performance of lithoplasty for treatment of calcified peripheral artery lesions. J Am Coll Cardiol. 2017;70:908-910.
3. Brodmann M, Werner M, Holden A, et al. Primary outcomes and mechanism of action of intra-vascular lithotripsy in calcified, femoropopliteal lesions: results of Disrupt PAD II. Catheter Cardiovasc Interv. 2019;93:335-342.
4. Adams G, Shammas N, Mangalmurti S, et al. Intravascular lithotripsy for treatment of calcified lower extremity arterial stenosis: initial analysis of the Disrupt PAD III study. J Endovasc Ther. 2020;27:473-480.
5. Brodmann M, Holden A, Zeller T. Safety and feasibility of intravascular lithotripsy for treatment of below-the-knee arterial stenoses. J Endovasc Ther. 2018;25:499-503.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement